The switch (called Haps59) consisted of a fusion between a yeast cytosine deaminase (an enzyme that can activate a prodrug) and the CH1 domain of the human p300 protein, a domain that can bind to the cancer marker HIF-1α. Here, EP300 is linked to cancer.